57th Annual Meeting Swiss Society of Nephrology SGN-SSN

Congress Kursaal Interlaken | December 4–5, 2025







www.swissnephrology.ch

Congress venue

www.congress-interlaken.ch

Congress Kursaal Interlaken Strandbadstrasse 44, 3800 Interlaken



■ | Table of contents

Invitation 2025	3
Organization	4
General information	5
Program at a glance	9
Invitation «SGN-SSN Networking-Dinner»	12
Exhibition	14
Association / Advertisement	16
Sponsored parallel symposia	17
Sponsors	19
Save the date	21

■ | Invitation 2025

Dear colleagues,

On behalf of the Scientific Committee, we cordially invite you to this year's Annual Meeting of the Swiss Society of Nephrology which will be held in **Interlaken on December 4-5, 2025**.

This year's conference will focus on **lifelong kidney care**. Although transition from pediatric to adult care has been improved in many centers, it remains a critical phase in kidney patients' disease trajectory. Pediatric Nephrologists are making efforts to let go, and adult Nephrologists are keen to appreciate the often complex disease histories of patients with congenital kidney disease.

We look forward to state of the art keynote lectures and a lively exchange between the pediatric and adult nephrology communities to learn from each other by strengthening our commonalities and valuing our differences. The meeting includes a platform to exchange ideas with leading experts and includes novel sessions including several symposia, short- and long oral presentations, elevator pitches, the Young Swiss nephrologist's award and the Publication award as well as the picture challenge.

Also, this year the **Symposium Pflege in der Nephrologie/Soins en Néphrologie/Cure in Nefrologia** will be held on December 4, 2025.

Another highlight of the conference will be the **Networking-Dinner on December 4, 2025**, to which you are also cordially invited. Enjoy a wonderful evening with the nephrologist family. In addition, the Young Swiss Nephrology award as well as the poster awards will be presented during a ceremony that evening – a tribute to the outstanding scientific work of our society.

Come and join us on December 4-5 in Interlaken!

Yours sincerely, The Congress Presidents

Organization

Congress Presidents

Sibylle Tschumi, Berne Wesley Hayes, Zurich

Ursula Dietrich, Berne (Pflege) Claudia Oeschger, Berne (Pflege)

Scientific Committee Johannes Loffing, Zurich (President)

Sophie de Seigneux, Geneva Nasser Dhavat, Hochfelden Fadi Fakhouri, Lausanne Britta George, Zurich Dela Golshayan, Lausanne Alexander Ritter, St. Gallen Stefan Rudloff, Berne Thomas Schachtner, Zurich

Daniel Sidler, Berne

Board of the SGN-SSN

President 2024-2025

Michael Dickenmann, Basel

President-elect 2024-2025

Pietro Cippà, Basel

Secretary

Felix Burkhalter, Basel

Treasurer

Fabien Stucker, Neuchâtel

Board Members

Andreas Fischer, Lucerne Dusan Harmácek, Zurich Maja Klein Lüthi, Burgdorf Johannes Loffing, Zurich Belén Ponte, Geneva Menno Pruiim. Lausanne Stephan Segerer, Aarau Daniel Sidler, Berne Markus Feldkötter. Lucerne François Verrey, Zurich

■ | General information

Congress venue Congress Kursaal Interlaken

Strandbadstrasse 44 | 3800 Interlaken

www.congress-interlaken.ch

Congress organization HPMS Consulting AG

Kreuzgasse 3 | 3713 Reichenbach i.K. www.hpms.ch | michael.herger@hpms.ch

Registration Online registration, prices and categories for the

congress as well as the Networking-Dinner available on

https://bit.ly/REGSGN2025

Included in the registration fees Access to the scientific sessions, congress program,

certificate of participation, coffee breaks and light

lunches.

The Networking-Dinner on Thursday, December 4, 2025 is not included and has to be booked separately (see

registration website above).

Accommodation is not included and has to be organized independently. You can book and pay for your desired

hotel rooms directly via the following link.

https://bit.ly/SGNSSN2025

We would like to ask you to book your overnight stay before October 22, 2025. On this date the contingent will

be greatly reduced.

Payment is made at the end of the registration process

and is only possible by online-payment (for example

credit card, debit card, twint)

Once you have registered, you will receive a confirmation

of registration, an e-ticket as well as

a receipt for any expense claims you may need.

Certificate of participation

The certificate of participation will be sent by e-mail (PDF) to all participants after the congress.

Cancellation

Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CHF 60. – for administrative costs. Thereafter no refund is possible. Legal jurisdiction is Berne.

Format of the event

The event is held in person, with no possibility to follow online via a live streaming. The congress language is English, «Pflegesymposien» in the respective national language. No simultaneous translation.

Industrial exhibition

An industrial exhibition will take place at the Congress venue. It will be open throughout the congress. Coffee (breaks) will be offered by exhibitors.

Oral Presentations

All oral and poster presentations must be given in English. Authors presenting an accepted paper must register and pay the appropriate registration fee. The Scientific Committee will select a number of abstracts which will be presented as oral presentations as such:

Long Oral Presentation (Thursday, December 4, 2025) The time slot for classical oral presentation is 10 minutes (8-minute presentation and 2-minute discussion).

Short Oral Presentatio (Thursday, December 4, 2025) The short oral presentation is designated to stimulate the discussion on posters. Each speaker will present the essence of his work in 3-minute presentation, followed by 2-minute discussion. The abstracts selected for this session will be also presented as classical **printed-out posters.** The poster format is DIN A0 (120x85cm) (height xwidth). The best posters will be awarded with a dedicated prize. The prizes will be awarded at the aperitif before the Networking-Dinner on Thursday, December 4, 2025 from approx. 19.00 hrs. The presence of the winners is desired.

Elevator pitch format (Friday, December 5, 2025)

Selected case reports will be presented in the «elevator pitch» format, an innovative, dynamic presentation format aiming at the active interaction with the public. The first part of all authors will have 1 minute to present 1 slide to convince the jury (= audience) of the quality of their work, in order to be selected for the second part and the presentation of additional 5-minute presentation (+2min-discussion).

Pecha-Kucha storytelling format YSN best oral presentation (Thursday, December 4, 2025) Selected abstracts for the YSN Best Oral Presentation will be presented in the innovative Pecha-Kucha storytelling format. The presentation consists of 20 slides (exactly 20) and each slide must be shown for 20 seconds. The best presentations will be awarded with a dedicated prize. The prizes will be awarded at the aperitif before the Networking-Dinner on Thursday, December 4, 2025 from approx. 19.00 hrs. The presence of the winners is desired.

Postwerwalk SGN Awards There will be no organized Posterwalk
The SGN Awards will take place during the Networking-Dinner on Thursday, December 4, 2025

Credits

Credit points will be given by the following societies:

SGN-SSN 16 credits
SGAIM-SSMIG in demand

ERA National Society of Nephrology Grant

ERA is promoting an initiative that involves the National Societies o Nephrology.

Specifically, ERA is offering an opportunity for each National Society consisting in three years of free ERA membership (Junior membership) plus one free Congress Membership to the annual ERA Congress; this ERA National Society of Nephrology Grant is given to a young person (under 40 years old) by the Swiss Society of Nephrology.


This year the grant will be chosen during the Young Swiss Nephrologists' Award session on Thursday, December 4, 2025.

TransCon® An innovative drug development platform

TransCon prodrugs have 3 components: a parent drug, carrier, and linker that temporarily binds the two.

TransCon Technology

TransCon refers to "transient conjugation." Our proprietary TransCon platform is designed to transiently link an inert carrier to a parent drug with known biology to achieve sustained release.



Ballimone Thurston PO, Marietin AC, Aglaipenen E, et al. Wooldy bengangerentegis, in treatment mise skilden milk. growth benness skildings skilden it beitilde sink. J. Cis. Endowind Mariek. J. CC, 1899 (2001–2008).

Ascerdin Present Bellinerierd Crobill

Seelekteirung 69 | HID9 Zürich www.ascendiapherraa.com

© Mirch 2025 Ascendie Phirms Switzerland Ganti-L. 06/2025 CH-COMMITCT-2500002 V1.0 Assendie[®], the Ascendie Phirms logo, the company

logo and lieneCon[®] are registered trademake owned by the Ascendic Planta Grano.



■ | Program at a glance

Thursday, December 4, 2025

	Theatersaal Room 1	Ballsaal Room 2
from 07.30	Registration and door o	pening Networking Area
08.30-08.45	Welcome address	
08.45-09.30	State of the Art: The UK Kidney Ecosystem - Enabling Clinical Research for adults and children Dr. Louise Oni	
09.30-10.10	Short oral 1	Short oral 2
10.10-10.20	Short	break
10.20-11.00	Short oral 3	Short oral 4
11.00-11.30	Coffee	e break
11.30-12.15	Parallel Symposium: Boehringer Ingelheim Insights from the CKD patient journey: where the shoe pinches	Parallel Symposium: CSL Vifor
12.15-13.00	State of the Art: Pregnancy in End-Stage renal disease Prof. Dr. Christopher T. Chan	Parallel Symposium: GlaxoSmithKline AG Viral Encounters in Kidney Care: Understanding the Burden of Disease and Role of Vaccination Prof. Dr. med. Uyen Huynh-Do Prof. Dr. med. Ulrich Heininger
13.00-13.45	Lunch break	
13.45-14.30	State of the Art: Advances in therapy for Nephrotic syndrome Prof. Dr. Moin Saleem	Parallel Symposium: Ascendis Pharma Experiences with rare diseases in nephrology - how do you recognise and treat these patients?
14.30-15.15	Parallel Symposium: Sanofi Nephrological perspectives on thrombotic microangiopathies: When every minute determines organ function Prof. Dr. Andreas Holbro Prof. Dr. Fadi Fakhouri	Parallel Symposium: AstraZeneca TREAT-CKD - New horizons in improving patient outcomes in complex challenges with CKD
15.15-15.45	Coffee	e break
15.45-17.35	Long Oral	
17.35-18.20	Young Swiss Nephrology Award	
18.20-22.00	Apéro and Networking-Dinner	

■ | Program at a glance

Pflege in der Nephrologie - Soin en Néphrologie - Cure in Nefrologia Thursday, December 4, 2025

	Club Casino Room 3
08.45-09.30	Pflegesymposium Implementierung und Evaluation der APN-Rolle auf der Dialyse/Nephrologie im USB Petra Meury
09.30-10.10	Pflegesymposium Transportkosten zum Dialysezentrum - Eine Herausforderung für die Patient:innen Sabrina Gröble
10.10-10.20	kurze Pause
10.20-11.00	Pflegesymposium Begleitung von Kindern mit chronischer Niereninsuffizienz und ihren Familien Rahel Gnägi
11.00-11.30	Kaffeepause
11.30-12.15	Pflegesymposium Der positive Umgang mit einer Nierenerkrankung Thomas Hunziker
12.15-13.00	Pflegesymposium Immersion in der Hochschullehre - «Bewegtes» klinisches Assessment in der Nephrologiepflege Prof. Dr. Elke Steudter
13.00-13.45	Mittagspause
13.45-14.30	Pflegesymposium L'utilizzo delle simulazioni in dialisi come strumento formativo per il personale Nadine Poletti Cacio Elisa Guerra
14.30-15.15	Pflegesymposium L'ipnosi nei pazienti dializzati, in particolare per la gestione di dolori Giovanni Isella
15.15-15.45	Kaffeepause
15.45-16.40	Pflegesymposium Pflege von Patient:innen mit eingeschränkter Nierenfunktion in der Langzeitinstitution Sabine Herzig
16.40-17.35	Pflegesymposium Kunststoffverpackungen rezyklieren mit KEIS Michael Gasser

■ | Program at a glance

Friday, December 5, 2024

	Theatersaal Room 1	Ballsaal Room 2
from 07.30	Door opening N	Networking Area
08.30-09.45	General Assembly SGN/SSN	
09.45-10.00	SGN Publication Award 2025	
10.00-10.15	Short break	
10.15-11.00	Parallel Symposium: Otsuka Future Perspectives of IgAN Manage- ment	Parallel Symposium: Roche Unlocking Better Outcomes: Advances in Immunotherapy for Lupus Nephritis Prof. Dr. Andrea Rubbert-Roth PD Dr. med. Harald Seeger
11.00-11.30	Coffee break	
11.30–12.15	State of the Art	Parallel Symposium: Novartis A new Era for managing IgAN + C3G
12.15-13.00	Parallel Symposium: Alnylam Experiences with rare diseases in nephrology - how do you recognise and treat these patients?	Parallel Symposium: Swedish Orphan Biovitrum AG The Future of C3G and IC-MPGN Treatment: Innovations and Implications for Adults and Adolescents
13.00-14.00	Lunch break	
14.00-14.45	Picture Challenge	
14.45-15.30	State of the Art: Kidney Care in an unequal World Dr. sc. med. Valerie Luyckx	
15.30-15.45	Farewell address	
	Club Casino Room 3	
10.15-11.00	Elevator Pitch	
11.30-12.00	Swiss Dialysis Registry	

■ | Invitation «SGN-SSN Networking-Dinner»



As every year, a highlight of the conference is the dinner on Thursday evening. We look forward to seeing many of you there.

Date Thursday, December 4, 2025

Time Starting at 18h20


Place «Ballsaal» Room at the Congress Kursaal Interlaken

Registration required and possible through the regular congress inscription



■ Notes	

■ | Plan of exhibition



■ | Exhibitors

Company	Booth
AIRG Suisse	D
Alexion Pharma GmbH	26
Alnylam Switzerland GmbH	28
Amgen Switzerland AG	16
Ascendis Pharma	1
Astellas Pharma AG	2
AstraZeneca AG	26
Boehringer Ingelheim (Schweiz) AG	15
Bracco Suisse SA	9
Chiesi SA	19
CSL Vifor	4
Devatis AG	13
EPA EPA	А
Forni Medical GmbH	18
Fresenius Medical Care (Schweiz) AG	3
GlaxoSmithKline AG	14
Hemotech Switzerland GmbH	7
MCM Medsys AG	12
Medtronic	21
MSD Merck Sharp & Dohme AG	22
Nova Biomedical Schweiz GmbH	11
Novo Nordisk Pharma AG	27
Novartis Pharma Schweiz AG	17
OM Pharma Suisse SA	8
Otsuka Pharmaceutical (Switzerland) GmbH	25
Rhythm Pharmaceuticals Germany GmbH	29
Roche Pharma (Schweiz) AG	30
Salmon Pharma GmbH	6
Sanofi-Aventis (Schweiz) AG	5
SRRQAP	10
Takeda Pharma AG	20
Theramed AG	24
Vantive GmbH	23
Verband Nierenpatienten Schweiz	С
Young Swiss Nephrology	В

■ | Association

Association pour l'Information et la Recherche sur les maladies rénales Génétiques (AIRG)



www.airg-suisse.org

Swiss renal registry and quality assessment program (srrqap)



Verband Nierenpatienten Schweiz (VNPS)



www.nierenpatienten.ch

Schweizerische Nierenstiftung



www.nierenstiftung.ch

Young Swiss Nephrology



www.youngswissnephrology.ch

Advertisements by

Sanofi-Aventis (Schweiz) AG

Ascendis Pharma

| Sponsored parallel symposia



Alnylam Switzerland GmbH Friday, December 5, 2025 – 12.15–13.00 Room «Theatersaal»



Ascendis Pharma

Thursday, December 4, 2025 - 13.45-14.30 Room «Ballsaal»



AstraZeneca AG

Thursday, December 4, 2025 – 14.30–15.15 Room «Ballsaal»



Boehringer Ingelheim (Schweiz) GmbH Thursday, December 4, 2025 – 11.30–12.15 Room «Theatersaal»

CSL Vifor

CSL Vifor

Thursday, December 4, 2025 - 11.30-12.15 Room «Ballsaal»



GlaxoSmithKline AG

Thursday, December 4, 2025 - 12.15-13.00 Room «Ballsaal»



Novartis Pharma Schweiz AG Friday, December 5, 2025 - 11.30-12.15 Room «Ballsaal»



Otsuka Pharmaceutical (Switzerland) GmbH Friday, December 5, 2025 - 10.15-11.00 Room «Theatersaal»



Roche Pharma (Schweiz) AG Friday, December 5, 2025 - 10.15-11.00 Room «Ballsaal»





Sanofi-Aventis (Schweiz) AG Thursday, December 4, 2025 – 14.30–15.15 Room «Theatersaal»

Swedish Orphan Biovitrum AG Friday, December 5, 2025 – 12.15–13.00 Room «Ballsaal»

Awards 2025/SGN-SSN



Publication Award

CSL Vifor

Poster Awards





YSN Awards

Kind thanks to all our sponsors

































Kind thanks to all our sponsors

Medtronic




























Vantive

■ | Save the date : SGN-SSN congress 2025

We would like to invite you to the

58th Annual Meeting of the Swiss Society of Nephrology SGN-SSN on December **3–4, 2026 –** Kursaal Bern



Please save the dates of December 3-4, 2026!

We look forward welcoming you in Berne next year!





For all Fabry patients, think Fabrazyme®

- at any stage of life*1-3
- independent of gender, genotype or phenotype1-3



The treatment for long-term^{4,5}



Nephroprotection



Cardioprotection



Neuroprotection

 $Fabrazyme^{\circ} \ is \ indicated \ as \ enzyme \ replacement \ the rapy \ for \ patients \ with \ Fabry \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ with \ Fabry \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ with \ Fabry \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ with \ Fabry \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ with \ Fabry \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ disease \ (alpha \ Galactosidase \ A \ deficiency). \ for \ patients \ disease \$

from 8 years old

1. Ortiz A et al., Mol Genet Metab 2018;123(4):416-427. 2. Wraith JE et al., J Pediatr 2008;152:563-570. 3. Ortiz A et al., J Med Genet 2016;53(7):495-502. 4. Banikazemi M et al., Ann Intern Med 2007;146(2):77-86. 5. Germain DP et al., J Med Genet 2015;52(5):353-358. 6. Fabrazyme® professional information February 2024, www.swissmedicinfo.ch. All references can be provided upon request.

Fabrazyme*. API: Agalsidase Beta. I: Enzyme replacement therapy for patients with Fabry disease (alpha Galactosidase A deficiency). D: 1 mg/kg body weight, once every two weeks as an intravenous infusion. The initial infusion rate should not exceed 0.25 mg/min (15 mg/hour). Cit. Life-threatening hypersensitivity (anaphylactic reaction) to any of the components. PC: It is to be expected that almost all patients will develop (gG antibodies against agalsidase beta within a period of three months. There will then be an increased risk of infusion-induced reactions. Special care is necessary in cases of repeated application. In case of infusion-related reactions, the infusion rate may be reduced and antihistamines, paracetamol, ibuprofen, and/or corticosteroids may be administered previously. In the event of severe a cute reactions, discontinue treatment immediately and begin appropriate medical treatment. The efficacy of Fabrazyme on the kidney function of patients with advanced kidney damage may be impaired. IA: Do not administer in combination with chloroquine, amiodarone, benoquin, or gentamicin due to possible inhibition of intracellular alpha-galactosidase activity. AE: headaches, paraesthesia, nausea, vomiting, chills, fever. P: 35 mg: 1 vial per box. DC: A: MAH: sanofi-aventis (switzerland) ag. 12/14 Vernier/GE. Last Updated: February 2024. For further information visit http://www.swissmedicinb.cc/h/.



